Abstract

During episodes of acute-inflammation high-density lipoproteins (HDL), the carrier of so-called good cholesterol, experiences a major change in apolipoprotein composition and becomes acute-phase HDL (AP-HDL). This altered, but physiologically important, HDL has an increased binding affinity for macrophages that is dependent on cell surface heparan sulfate (HS). While exploring the properties of AP-HDL:HS interactions we discovered that HS caused significant remodeling of AP-HDL. The physical nature of this change in structure and its potential importance for cholesterol efflux from cholesterol-loaded macrophages was therefore investigated. In the presence of heparin, or HS, AP-HDL solutions at pH 5.2 became turbid within minutes. Analysis by centrifugation and gel electrophoresis indicated that AP-HDL was remodeled generating novel lipid poor particles composed only of apolipoprotein AI, which we designate β2. This remodeling is dependent on pH, glycosaminoglycan type, is promoted by Ca2+ and is independent of protease or lipase activity. Compared to HDL and AP-HDL, remodeled AP-HDL (S-HDL-SAA), containing β2 particles, demonstrated a 3-fold greater cholesterol efflux activity from cholesterol-loaded macrophage. Because the identified conditions causing this change in AP-HDL structure and function can exist physiologically at the surface of the macrophage, or in its endosomes, we postulate that AP-HDL contains latent functionalities that become apparent and active when it associates with macrophage cell surface/endosomal HS. In this way initial steps in the reverse cholesterol transport pathway are focused at sites of injury to mobilize cholesterol from macrophages that are actively participating in the phagocytosis of damaged membranes rich in cholesterol. The mechanism may also be of relevance to aspects of atherogenesis.

Introduction

There is substantial evidence that high density lipoprotein (HDL) and its major apolipoprotein, apoA-I, can inhibit the initiation and progression of atherosclerosis [1–4]. The most widely accepted explanation for these effects is based on HDL’s central role in reverse cholesterol transport (RCT), the transport of cholesterol from peripheral cells, like macrophages, to the liver for reuse or excretion as bile acids. The HDL fraction in plasma is composed of a polydisperse population of particles ranging from lipid poor small discoidal pre-β-HDL, to larger lipid-rich spherical HDL [5]. Pre-β-HDL collects cholesterol and phospholipids from parenchymal cells and in conjunction with lecithin cholesterol acyltransferase (LCAT), which transfers acyl groups from phosphatidylcholine to free cholesterol, the cholesterol is converted to an ester that is retained in the core of mature spherical HDL particles. ApoA-I is normally the most abundant protein (70–100%) on the various classes of HDL and plays a critical role in their functions. However, during the acute-phase response, the initial systemic reaction to inflammation, the plasma concentration of apoA-I declines substantially [6,7] and is replaced by serum amyloid A (SAA), an acute-phase protein [8,9].

SAA was identified in the early 1970’s as the plasma protein responsible for forming tissue deposits called amyloid (AA-type) seen clinically in diseases with underlying persistent acute inflammation [10,11]. Soon after its discovery, SAA was shown to be an acute-phase protein produced by the liver within hours of tissue injury regardless of cause. Its plasma concentration can increase a 1000-fold (1 μg/ml to 1 mg/ml) within 24 h and return to baseline levels over a 7–10 day period providing the tissue insult is short-lived [12,13]. In plasma SAA is associated with HDL [13,14] and during severe inflammation can contribute up to 80% of its apo-protein composition [15,16]. The displaced apoA-I is rapidly cleared by the liver and kidneys [17], and together with a sharp decline in apoA-I gene expression during inflammation [18,19] the apoA-I plasma half-life is reduced from 12 to 3.5 hr [6] with an overall 50–70% reduction in plasma concentration [19–22]. Since apoA-I plays such an important role in RCT the apolipoprotein compositional changes of HDL during inflammation have been viewed as being pro-atherogenic, a conclusion that may be premature.

An ancient protein conserved from echinoderms to humans (500–650 mya), SAA has no known homologue and until recently no clear function [23]. Several years ago we postulated that given SAA’s association with HDL its function must be linked to that of...
HDL in RCT. The initial evidence for this idea centered on the observation that SAA decreases AP-HDL’s binding affinity for hepatocytes by 2-fold while increasing its affinity for macrophages by up to 5-fold, and macrophages from inflamed mice have a 5-fold increase in binding sites for AP-HDL [24–26]. The binding to macrophage is dependent on the cell surface glycosaminoglycan, heparan sulfate (HS) [27] and likely involves a HS binding site in the C-terminal end of SAA [28]. Further investigations have shown that SAA also enhances macrophage uptake of AP-HDL [27,29–31] and once inside the cell, SAA acts to mobilize cellular cholesterol for export [32–36]. Through the actions of two separate domains, SAA increases neutral cholesterol ester hydrolase (nCEH) and inhibits acyl-CoA cholesterol acyltransferase (ACAT) activities [34–36]. Intracellular cholesterol balance is thereby shifted from cholesterol ester to free cholesterol, the form which can be readily exported by ATP-binding cassette transport proteins (ABCA1, ABCG1), to extra-cellular HDL acceptors [37].

Although SAA’s strong evolutionary conservation and regulated expression implies that its function must be of significant benefit to the host, it has been difficult to explain the survival advantage of promoting cholesterol mobilization and efflux during a period of apparent decline in apoA-I-based RCT potential. To address this question we now provide the first evidence that a rapid non-enzymatic mechanism exists for remodeling AP-HDL into apoA-I rich particles that have enhanced cholesterol-accepting activity complementing SAA’s function.

Results

HS causes AP-HDL to aggregate at pH 5.2

AP-HDL binding to macrophages requires cell surface HS-proteoglycans [27] and a HS binding site has been identified at the C-terminus of SAA [28]. Preliminary in vitro binding assays with AP-HDL revealed that incubation with commercially available HS, heparin (16 kDa) or heparin3000 (3 kDa) at mildly acidic pH (pH 5.2), caused AP-HDL to rapidly undergo a phase change and become visibly turbid (Figure 1A). This effect did not occur with HDL (Figure 1A) and was independent of protease or lipase activity. The results were the same in the presence and absence of protease inhibitors or EDTA (data not shown), and the effect of lipases are reported to take several hours to influence HDL structure as opposed to that seen with heparin, or HS, which occurs in minutes (Figure 1B).

The quantity of aggregate formed was saturable at sub-stoichiometric concentrations of heparin or HS (approx. 10 μM apoA-I to 4 μM heparin or HS) and reached 50% saturation in 5 min (Figure 1B). Centrifugation (10,000g, 3 min.) produced supernatant fractions (S-HDL-SAA) clear of aggregates and pelleted aggregates (A-HDL-SAA) with a protein content proportional to the degree of turbidity, saturating at approximately 35% of total AP-HDL protein content (data not shown). Aggregation was not produced with other glycosaminoglycans, such as chondroitin or dermatan sulfates, indicating a degree of specificity for HS and not produced with other glycosaminoglycans, such as chondroitin

β2-particles have exceptional cholesterol accepting properties

The S-HDL-SAA fraction is an exceptional acceptor of cholesterol from cholesterol-laden macrophages. Whether generated with heparin, or HS (+1 mM Ca²⁺), the resulting S-HDL-SAA had a 2.5 to 3-fold greater cholesterol accepting activity relative to AP-HDL (Figure 3A). The bulk of the exported cholesterol was derived from de-esterified cellular cholesterol esters (Figure 3B). Analysis of S-HDL-SAA cholesterol content by thin layer chromatography confirmed that only free-cholesterol was accepted from cholesterol-loaded cells (data not shown). The presence of heparin in the S-HDL-SAA fraction did not contribute to this activity since its removal by ion exchange chromatography had no effect on the proportion, or rate of cholesterol removed from the cells (Figure 3C). Depletion of the β-components from the S-HDL-SAA fraction clearly abolished its ability to promote cholesterol efflux (Figure 3C). Heparin treated HDL also produced some β1 but no increase in activity was evident and pure apoA-I demonstrated poor efflux activity. These data point to the β2 species as the one playing a significant role in macrophage cholesterol efflux.

Discussion

When macrophages take up cholesterol any excess not required for membrane homeostasis or other functions is esterified by ACAT and stored in ester form. These cholesterol-ester loads can be significant for macrophages transforming them into “foam cell”, one of the earliest cellular indicators of atherogenesis in arterial disease. The first step in the mobilization and export of excess stored cholesterol via the RCT pathway is the de-esterification of cholesterol-esters accomplished by nCEH. The resulting free cholesterol moves through the cell membrane either by passive diffusion or active transport by ABC transport proteins (ie. ABCA1, ABCG1) for collection and transport by apoA-I-rich lipoproteins.

Recent studies have demonstrated that the acute-phase protein SAA contains two domains one of which inhibits ACAT activity and the other enhances nCEH activity thereby substantially shifting the balance of cellular cholesterol to that of free cholesterol available for efflux [34–36]. Neither of these two activities is affected by apoA-I [33–35] and since β1 and β2 described herein consist entirely of apoA-I it is not likely that they directly promote the de-esterification of stored cholesterol esters. Furthermore, HDL treated with heparin generated low levels of β1, but not β2. Although we cannot completely rule out the possibility that β1 contributed to the increase in cholesterol efflux observed for S-HDL-SAA, its presence did not improve the efflux activity for...
HDL. Also, the electrophoretic mobility of β1 suggests that it is composed of lipid free apoA-I, which was not an efficient acceptor of cholesterol from macrophages in our assays (Figures 3A and 3B). Conversely, SAA, or its active peptide domains, can influence ACAT and nCEH activities even in the absence of cholesterol export but requires a cholesterol acceptor, such as HDL, for rapid and efficient macrophage cholesterol efflux [33,35]. Efflux promoted by SAA was demonstrated to be dependent on the activity of ABCA1 and/or ABCG1 [34]. Moreover, we have shown previously that the in vitro effect of AP-HDL (i.e. HDL-SAA) on macrophage cholesterol efflux can be demonstrated in vivo [34–36,42]. Cholesterol-laden macrophages when injected intravenously into normal mice and allowed to acclimatize themselves for 24 h rapidly export their cholesterol in response to HDL-SAA, or SAA's active domains, in the same manner as they do in vitro. Our present data argue that apoA-I in the form of the β2 component is an exceptionally efficient cholesterol acceptor of exportable cholesterol. We therefore postulate that AP-HDL contains latent functionalities that become active when it associates with macrophage cell surface/endosomal HS at least at sites of injury and possibly elsewhere. The α'-component of S-HDL-SAA contains SAA, which by virtue of its two active domains drives

Figure 1. The aggregation of AP-HDL at mildly acid pH when incubated with heparin or HS. A) HDL or AP-HDL at pH 5.2 or 7.2 were incubated for 30 min with increasing concentrations of heparin, HS+1 mM Ca²⁺, CS (chondroitin sulfate) or DS (dermatan sulfate). The absorbance at 400 nm was then plotted against glycosaminoglycan concentration. B) AP-HDL (1 mg/ml) at pH 5.2 in 125 mM NaCl, 25 mM Na acetate, was incubated with 0.2 mg/ml heparin and absorbance at 400 nm read at intervals to 60 min. C) AP-HDL (1 mg/ml) incubated for 20 min at 37°C with heparin, or different chemically modified heparins, at 0.1 mg/ml as described in Panel B; CR-hep. = carboxy-reduced heparin; de-NS-hep. = N-desulfated heparin; de-2-O-hep. = de-2-O-sulfated heparin; de-6-O-hep. = de-6-O-sulfated heparin; de-OS-hep. = de-2,6-O-sulfated heparin. D) Incubations, supplemented with 1 mM Ca²⁺, greatly increased the AP-HDL aggregation activity of HS. AP-HDL was incubated at pH 5.2 with heparin, HS, CS, DS with or without Ca²⁺, as in C. The results in C) and D) are the mean±SEM of 3 experiments. The results with CS and DS were virtually identical.

doi:10.1371/journal.pone.0003867.g001
the de-esterification of cholesterol esters and prevents its re-esterification. The β2-component is the efficient extracellular cholesterol acceptor that gets targeted to macrophages by virtue of AP-HDL’s increased affinity and the macrophages increased number of binding sites for AP-HDL.

The data presented herein suggests that AP-HDL on binding to HS under mildly acidic pH associated with normal membrane electrostatics [43,44] or endosomal compartments, can rapidly be remodeled generating novel apoA-I-rich particles that function physiologically to mobilize cholesterol from cholesterol-laden macrophages at sites of tissue injury. The micro-environmental conditions favoring HS-based remodeling of AP-HDL may occur at sites of injury, and potentially elsewhere where macrophages are actively scavenging damaged cell membranes. Macrophage are exceptional at endosomal acidification reaching pH 5.0–5.5 within 10 min of endocytosis [45]. Furthermore, sites of tissue injury can become acidic due to reduced blood supply leading to hypoxia which forces cells to switch to anaerobic glycolysis resulting in lactic acidosis.

We believe that the described mechanism for remodeling AP-HDL explains why AP-HDL is consistently more effective than HDL as a promoter of macrophage cholesterol efflux [34] (Figure 3A). Allowing AP-HDL to interact with heparin/HS in vitro, likely replicates, under optimum conditions, the physiological process that takes place at the surface of the macrophage at sites of injury. This re-modeling of AP-HDL takes place in minutes, does not require lipases and is a natural consequence AP-HDL’s interaction with HS likely mediated through a HS-binding site identified on SAA [28].

As we have argued previously [8] the actions of SAA may help conserve cholesterol pools during severe injury. The biosynthesis of cholesterol is a significant metabolic investment requiring 30-enzymatic steps. SAA’s influence would decrease cholesterol loss, allow its recycling and compensate for any injury related decline of cholesterol biosynthesis/availability that is necessary for post-injury tissue repair. SAA’s activities may also improve the cellular performance of macrophages at sites of injury by limiting foam cell formation. Evidence for this latter point has recently been provided using an experimental atherogenesis model, where the development of aortic lipid lesions in apo-E-/- mice was effectively prevented and even reversed by intravenous injections of liposomal formulations of synthetic peptides corresponding to SAA’s two functional domains [36].

Methods
Chemicals
All chemicals were reagent grade and purchased from Fisher Scientific (Nepean, Ontario), Sigma (St. Louis, MO), ICN (Aurora, OH), or BioRad (Hercules, CA). Dulbecco’s modified Eagle’s medium (DMEM) and FBS were purchased from Life Technologies (Burlington, Ontario). Radiolabeled [1,2,6,7-3H(N)] cholesterol (82 Ci/mmol) was obtained from DuPont NEN (Boston, MA). Glycosaminoglycans and SIGMAFAST™ Protease Inhibitor were purchased from Sigma (St. Louis, MO).

Purification of HDL, AP-HDL and apoA-I
To increase plasma concentrations of SAA in CD1 mice an acute-inflammatory state was induced by a subcutaneous injection of 0.5 ml 2% (w/v) AgNO₃ [46]. After 24 h, mice were sacrificed by CO₂ narcosis and exsanguinated by cardiac puncture preventing clotting with EDTA. High density lipoprotein (HDL)
containing SAA (AP-HDL) was isolated from inflamed plasma by sequential density flotation [47]. The density of the plasma was adjusted to 1.063 g/ml with NaBr and centrifuged at 175,000 g for 18 h in a 70.1Ti rotor (Beckman) at 10 °C. The top layer containing VLDL/LDL was removed and discarded. The pooled infranatants were adjusted to a density of 1.21 g/ml and re-centrifuged at 250,000 g for 24–36 h at 10 °C. The top layer (AP-HDL) was aspirated, pooled, and dialysed against 20 mM Tris-HCl, 0.15 M NaCl, 0.1% (w/v) EDTA, pH 7.5, for 18 h. Lipoproteins were assessed by reverse phase-high pressure liquid chromatography on a C18-Vydac column as previously described [28]. The eluant containing apoA-I was collected, lyophilized and stored at -20 °C.

**Figure 3. Cholesterol efflux from J774 monocytes incubated with different lipoproteins.** Monolayer cultures of J774 monocytes were loaded with cholesterol (22.7 µg/well) and [3H]-cholesterol (0.45 µCi) overnight, washed twice with DMEM in 0.2% BSA (1 ml) and once with DMEM alone. Cholesterol-loaded cells were then incubated with different lipoprotein preparations (50 µg/ml) in 1 ml DMEM, 0.2% BSA; A) S-HDL-SAA prepared with heparin; S-HDL-SAA prepared with HS+1 mM Ca2+; A-HDL-SAA; AP-HDL; HDL; S-HDL prepared with heparin. B) Lipid was extracted from cell and analyzed by thin-layer chromatography as described previously [35] to determine the amount of [3H]-cholesteryl ester remaining in the cells relative to cholesterol-loaded cells. C) S-HDL-SAA; S-HDL-SAA preincubated with DEAE-Sepharose to remove any heparin; S-HDL-SAA recentrifuged at 1.25 g/ml to remove lipid poor species, A-HDL-SAA and delipidated apoA-I. Aliquots of medium were taken at the time intervals shown and the quantity of [3H]-cholesterol exported from the cells determined and expressed as a percentage of total [3H]-cholesterol in loaded cells before incubations.

doi:10.1371/journal.pone.0003867.g003

**AP-HDL and HDL aggregation**

Lipoproteins were applied to a Sephadex G-50 column (1×10 cm) equilibrated in 0.15 M NaCl. Void fractions were collected and adjusted to 2 mg/ml protein, then stored on ice. HDL or AP-HDL were diluted to a final concentration of 1 mg/ml in 25 mM sodium acetate, 125 mM NaCl, pH 5.2 or pH 7.2 containing increasing concentrations of heparin, HS, chondroitin sulfate (CS) or dermatan sulfate (DS). In some experiments a broad spectrum protease inhibitor (Sigma) was included to judge the involvement of proteolysis. Upon mixing tubes were incubated in a water bath at 37 °C for 0–60 min. Tubes were re-mixed and absorbance read at 400 nm in a quartz cuvette (path length 1 cm). Aggregates were collected by centrifugation at 10,000 g for 3 min.
producing a pellet and clarified supernatant. Pellet was washed once, re-suspended in buffer and both pellet (A-HDL-SAA) and supernatant fractions (S-HDL-SAA) were dialysed against 20 mM HEPES, 150 mM NaCl, pH 7.2, at 4°C. S-HDL-SAA was concentrated to 1–2 mg/ml by ultrafiltration using a Centricon YM10 concentrator and stored on ice until use. Heparin was purified from some S-HDL-SAA samples by anion exchange chromatography on DEAE-Sepharose-CL 4B column [48]. After centrifugation to pellet the aggregates containing S-HDL-SAA fraction was applied to the column pre-equilibrated with containing the S-HDL-SAA was collected with heparin (30 mM) was mixed with 0.2 ml of cholesterol dissolved in ethanol (5 mg/ml) and 20 μl of [3H]cholesterol (20 μCi). The mixture was incubated at 37°C for 1 h. For cholesterol loading and labeling of the J774 cells, 30 μl of the MCD-cholesterol complex was added to 1 ml of DMEM in 0.2% BSA overnight. After incubation, the cells were washed twice with DMEM in 0.2% BSA (1 ml) and once with DMEM alone prior to cholesterol efflux studies that were carried out in DMEM-BSA.

Acknowledgments

We wish to thank Elizabeth Hearn and Cindy Lentz for their able technical support.

Author Contributions

Conceived and designed the experiments: SPT RK JBA. Performed the experiments: SPT JBA. Analyzed the data: SPT JBA. Contributed reagents/materials/analysis tools: SPT RK JBA. Wrote the paper: RK JBA.

References

1. Wilson PW, Abbott RD, Castelli WP (1988) High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 8: 737–741.
2. Barter PJ, Rye KA (2006) Relationship between the concentration and antiatherogenic activity of high-density lipoproteins. Circ Res 10: 399–403.
3. Assman G, Goto AM Jr (2004) HDL cholesterol and protective factors in atherosclerosis. Circulation 109: IIA–II14.
4. Rader DJ (2007) Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med 4: 102–109.
5. Lewis GF, Rader DJ (2005) New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96: 1221–1232.
6. Tan C, Kiełkiewicz R (1990) Apolipoprotein-A1 and Apolipoprotein SAA Halves: During Acute Inflammation and Amyloidogenesis. Biochim Biophys Acta 1049: 295–300.
7. Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, et al. (2006) Reciprocal association of cholesterol efflux, serum amyloid A gene expression, and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol 26: 1006–1013.
8. Manley PN, Ancsin JB, Kiełkiewicz R (2006) Rapid recycling of cholesterol: The joint biologic role of C-reactive protein and serum amyloid A. Med Hypotheses 66: 784–792.
9. Gahar C, Knudsen I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448–454.
10. Benandt EP, Eriksen N, Hermodson MA, Ericson LH (1971) The major proteins of human and monkey amyloid substance: common properties including unusual N-terminal amino acid sequences. FASEB J 51: 2773–2776.
11. Levin M, Franklin EC, Frangione B, Pres M (1972) The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J Clin Invest 51: 2773–2776.
12. Benandt EP, Eriksen N (1957) Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci USA 74: 4025–4029.
13. Benandt EP, Eriksen N, Hanson RH (1957) Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. Proc Natl Acad Sci USA 76: 4092–4096.
14. Benandt EP, Hoffman JS, Eriksen N, Parmelee DC, Walsh KA (1982) SAA, an apoprotein of HDL: its structure and function. Ann N Y Acad Sci 309: 183–189.
15. Clifton PM, Mackinnon AM, Barter PJ (1985) Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res 26: 1398–1390.
16. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Kindy M, et al. (1986) Serum amyloid A-containing human high density lipoprotein 3: Density, size, and apoprotein composition. J Biol Chem 261: 9644–9651.
17. Graversen JH, Castro G, Kandussi A, Nielsen H, Christensen EI, et al. (2000) A pivotal role of the human kidney in catabolism of HDL. Protein components of apolipoprotein-A1 and A-IV but not of A-II. Lipids 35: 463–470.
18. Kabab C, Carpelán CA, Steer RW, Moreno JP (1996) Transcriptional regulation of serum amyloid A gene expression. J Biol Chem 271: 8453–8461.
19. Navarro MA, Carpentero R, Acián S, Arbones-Mainar JM, Callera L, et al. (2005) Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation. Cytokine 31: 63–73.
20. Cabana VG, Siegel JN, Sabessin SM (1989) Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res 30: 39–49.
21. Cabana VG, Lukens JR, Rice KS, Hawkins TJ, Getz GS (1996) HDL content and apoprotein composition in acute phase response in three species. Triglyceride enrichment of HDL, a factor in its decrease. J Lipid Res 37: 2662–2674.
22. van Leeuwen HJ, Heezius EG, Dallinga GM, van Strijp JA, Verhoef J, et al. (2003) Lipoprotein metabolism in patients with severe cirrhosis. Crit Care Med 31: 1359–1366.
23. Uhlar CM, Whitehead AS (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265: 501–523.
24. Kiełkiewicz R, Subrahmanyan L (1992) Serum amyloid A changes high density lipoprotein’s cellular affinity: a clue to serum amyloid A’s principal function. Lab Invest 66: 776–785.
25. Hayat S, Raynes JG (1997) Serum amyloid A has a little effect on high density lipoprotein (HDL) binding to U937 monocytes but may influence HDL mediated cholesterol transfer. Biochem Soc Trans 25: 8340.
26. Hayat S, Raynes JG (2000) Acute phase serum amyloid A protein increases high density lipoprotein binding to human peripheral blood mononuclear cells and an endothelial cell line. Scand J Immunol 51: 141–146.
27. Rocken C, Kiełkiewicz R (1997) Binding and endocytosis of high density lipoprotein from healthy (HDL) and inflamed (HDLa) donors by murine macrophages in-vitro. A light and electronmicroscopic investigation. Amyloid 4: 259–273.
28. Ancsin JB, Kiełkiewicz R (1999) The heparin/heparan sulfate-binding site on apor amyloid A: implications for the therapeutic intervention of amyloidosis. J Biol Chem 274: 7172–7181.
29. Banka CL, Yuan T, De Beer MC, Kindy M, Curtiss LK, et al. (1995) Serum amyloid A (SAA): Influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 36: 1058–1065.
30. Klave-Beckerman B, Manaloort J, Leipnickis JJ (2001) Binding, trafficking and accumulation of serum amyloid A in peritoneal macrophages. Scand J Immunol 53: 393–400.
31. Kinkley SM, Baghazz W, Tan SP, Kiełkiewicz R (2006) The path of murine serum amyloid A through peritoneal macrophages. Amyloid 13: 123–134.
32. Lindhorst E, Young D, Baghazz W, Hyland M, Kiełkiewicz R (1997) Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse. Biochim Biophys Acta 1339: 143–154.
33. Ely S, Bonaterra R, Ancsin JB, Kindy M, Kiełkiewicz R (2001) The in-vitro influence of serum amyloid A isoforms on enzymes that regulate the balance between esterified and un-esterified cholesterol. Amyloid 8: 169–181.
34. Tan SP, Fleumx A, Holme J, Kiełkiewicz R (2002) Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J Lipid Res 43: 1410–1420.
35. Kiełkiewicz R, Tan SP (2003) Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1. J Lipid Res 44: 2257–2269.
36. Tan SP, Ancsin JB, Tan R, Kiełkiewicz R (2005) Peptides derived from serum amyloid A present, and reverse, aortic lipid lesions in apolipoprotein E-/- mice. J Lipid Res 46: 2091–2101.
37. Jessup W, Gelssen IG, Gaus K, Kritharides L (2006) Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol 17: 247–257.
38. Benjwal S, Jayaraman S, Gursky O (2005) Electrostatic effects on the stability of ducidual high-density lipoproteins. Biochemistry 44: 10218–10226.
39. Jayaraman S, Gantz DL, Gursky O (2006) Effects of salt on the thermal stability of human plasma high-density lipoprotein. Biochemistry 45: 4620–4628.
40. Yokoyama S, Tajima S, Yamamoto A (1982) The process of dissolving apolipoprotein A-I in an aqueous buffer. J Biochem 91: 1267–1272.
41. Thomas MJ, Bhat S, Sorci-Thomas MG (2008) Three-dimensional models of HDL apoA-I: implications for its assembly and function. J Lipid Res 49: 1875–1883.
42. Kisilevsky R, Tam SP, Ancsin JB (2006) The anti-atherogenic potential of serum amyloid A peptides. Curr Opin Investig Drugs 9: 265–273.
43. Cevc G (1990) Membrane electrostatics. Biochim Biophys Acta 1031: 311–382.
44. Mulgrew-Nesbitt A, Diraviyam K, Wang J, Singh S, Murray P, et al. (2006) The role of electrostatics in protein-membrane interactions. Biochim Biophys Acta 1761: 812–826.
45. Geisow MJ, Evans WH (1984) pH in the endosome. Measurements during pinocytosis and receptor-mediated endocytosis. Exp Cell Res 150: 36–46.
46. Axelrad MA, Kisilevsky R, Willner J, Chen SJ, Skinner M (1982) Further characterization of amyloid enhancing factor. Lab Invest 47: 139–146.
47. Havel RJ, Eder HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoprotein in human serum. J Clin Invest 34: 1345–1353.
48. Lindahl B, Lindahl U (1997) Amyloid-specific heparan sulfate from human liver and spleen. J Biol Chem 272: 26091–26094.